Ying-Cing Lin

Ying-Cing Lin is a Senior Scientist in Immuno-Oncology at Ensoma, where responsibilities include establishing a humanized mouse model to validate the Engenious™ platform for immuno-oncology applications. Prior experience includes a postdoctoral fellowship at the Ragon Institute of MGH, MIT, and Harvard, where Ying-Cing Lin developed a CRISPR/Cas9 platform for generating human B cell receptor knock-in mice, facilitating pre-clinical immune characterization for vaccine development. Ying-Cing Lin's academic background includes a Ph.D. in Pharmacology from National Taiwan University, where research focused on the regulation of pro-inflammatory and anti-inflammatory responses in innate immunity and the mechanistic roles of spleen tyrosine kinase in immune signaling. An M.S. and a B.S. in Pharmacy were also earned at National Taiwan University.